Avalon GloboCare (NASDAQ:ALBT) Releases Earnings Results

Avalon GloboCare (NASDAQ:ALBT – Get Rating) posted its quarterly earnings results on Monday. The company reported ($0.28) earnings per share (EPS) for the quarter, reports. Avalon GloboCare had a negative net margin of 1,053.75% and a negative return on equity of 662.37%. The business had revenue of $0.30 million during the quarter.

Avalon GloboCare Stock Performance

ALBT opened at $1.84 on Thursday. The company has a current ratio of 0.27, a quick ratio of 0.66 and a debt-to-equity ratio of 2.11. Avalon GloboCare has a fifty-two week low of $1.65 and a fifty-two week high of $8.05. The stock has a 50-day simple moving average of $1.94.

Institutional Trading of Avalon GloboCare

Several institutional investors and hedge funds have recently modified their holdings of ALBT. State Street Corp raised its position in Avalon GloboCare by 70.7% in the 1st quarter. State Street Corp now owns 19,120 shares of the company’s stock valued at $38,000 after buying an additional 7,920 shares during the last quarter. Virtu Financial LLC purchased a new stake in shares of Avalon GloboCare in the first quarter valued at about $41,000. Finally, Geode Capital Management LLC bought a new position in shares of Avalon GloboCare during the fourth quarter valued at about $90,000. 0.92% of the stock is owned by hedge funds and other institutional investors.

Avalon GloboCare Company Profile

(Get Rating)

Avalon GloboCare Corp. is a clinical-stage biotechnology company, which engages in the development of immune effector cell therapy and laboratory services. It operates through the Real Property Operating and Medical Related Consulting Services segments. The Real Property Operating segment includes property management fees, property insurance, real estate taxes, depreciation, repairs and maintenance fees, utilities and other expenses related to rental properties.